Plus Therapeutics (PSTV) Total Liabilities (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Total Liabilities data on file, last reported at $8.0 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $8.0 million, down 77.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.0 million (down 77.72% YoY), and the FY2025 annual result was $12.3 million, down 20.88% from the prior year.
• Total Liabilities retreated to $8.0 million in Q1 2026 per PSTV's latest filing, from $12.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $35.7 million in Q1 2025 and troughed at $7.3 million in Q2 2025.
• A 5-year average of $13.7 million and a median of $12.2 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities surged 241.34% in 2025, then tumbled 77.72% in 2026.
• A 5-year view of Total Liabilities shows it stood at $17.4 million in 2022, then dropped by 26.9% to $12.7 million in 2023, then increased by 22.35% to $15.6 million in 2024, then fell by 20.88% to $12.3 million in 2025, then sank by 35.48% to $8.0 million in 2026.
• Business Quant data shows PSTV's Total Liabilities at $8.0 million in Q1 2026, $12.3 million in Q4 2025, and $13.6 million in Q3 2025.